Frequency and Predictors of HIV-Related Cognitive Impairment in East Africa: The Africa Cohort Study (AFRICOS).
Adolescent
Adult
Aged
Aged, 80 and over
Analysis of Variance
Anti-HIV Agents
/ therapeutic use
CD4 Lymphocyte Count
Cognitive Dysfunction
/ complications
Cohort Studies
Cross-Sectional Studies
Female
HIV Infections
/ complications
Humans
Kenya
Linear Models
Logistic Models
Male
Middle Aged
Multivariate Analysis
Odds Ratio
Tanzania
Uganda
Young Adult
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 02 2020
01 02 2020
Historique:
pubmed:
7
1
2020
medline:
27
6
2020
entrez:
7
1
2020
Statut:
ppublish
Résumé
Medication adherence is a critical issue in achieving viral suppression targets, particularly in resource-limited countries. As HIV-related cognitive impairment (CI) impacts adherence, we examined frequency and predictors of CI in the African Cohort Study. Cross-sectional examination of enrollment data from President's Emergency Plan for AIDS Relief supported clinic sites. In a 30-minute cognitive assessment, CI was defined as -1SD on 2 tests or -2SD on one, as compared with 429 controls. We performed univariable and multivariable logistic and linear models examining clinical and demographic factors associated with CI and global neuropsychological performance (NP-6). Two thousand four hundred seventy-two HIV+ participants from Kenya (n = 1503), Tanzania (n = 469), and Uganda (n = 500). The mean (SD) age was 39.7 (10.7) years, and 1452 (59%) were women. The majority reported completing or partially completing primary school (n = 1584, 64%). Mean (SD) current and nadir CD4 count were 463 (249) and 204 (221) cells/mm, respectively; 1689 (68%) were on combination antiretroviral therapy. Nine hundred thirty-nine (38%) HIV+ versus 113 (26%) HIV- individuals showed CI: (P < 0.001). We found significant effects of literacy [odds ratio (OR): 0.3; 95% CI: 0.2 to 0.4; P < 0.001] and World Health Organization stage 4 (OR: 1.5; 95% CI: 1.0 to 2.q; P = 0.046) on CI. Tanzanians (OR: 3.2; 95% CI: 2.4 to 4.3; P < 0.001) and Kenyans (OR: 2.0; 95% CI: 1.6 to 2.6; P < 0.001) had higher risk of CI compared with Ugandans. Results were relatively unchanged in predictive models of NP-6, with the only difference being an additional significant effect of current CD4 cell count (coeff: 0.0; 95% CI: 0.0 to 0.0; P = 0.005). Literacy, country, World Health Organization stage, and current CD4 cell count were associated with increased risk of cognitive dysfunction. Our findings help optimize care practices in Africa, illustrating the importance of strategies for early and effective viral-immunological control.
Sections du résumé
BACKGROUND
Medication adherence is a critical issue in achieving viral suppression targets, particularly in resource-limited countries. As HIV-related cognitive impairment (CI) impacts adherence, we examined frequency and predictors of CI in the African Cohort Study.
SETTING
Cross-sectional examination of enrollment data from President's Emergency Plan for AIDS Relief supported clinic sites.
METHODS
In a 30-minute cognitive assessment, CI was defined as -1SD on 2 tests or -2SD on one, as compared with 429 controls. We performed univariable and multivariable logistic and linear models examining clinical and demographic factors associated with CI and global neuropsychological performance (NP-6).
RESULTS
Two thousand four hundred seventy-two HIV+ participants from Kenya (n = 1503), Tanzania (n = 469), and Uganda (n = 500). The mean (SD) age was 39.7 (10.7) years, and 1452 (59%) were women. The majority reported completing or partially completing primary school (n = 1584, 64%). Mean (SD) current and nadir CD4 count were 463 (249) and 204 (221) cells/mm, respectively; 1689 (68%) were on combination antiretroviral therapy. Nine hundred thirty-nine (38%) HIV+ versus 113 (26%) HIV- individuals showed CI: (P < 0.001). We found significant effects of literacy [odds ratio (OR): 0.3; 95% CI: 0.2 to 0.4; P < 0.001] and World Health Organization stage 4 (OR: 1.5; 95% CI: 1.0 to 2.q; P = 0.046) on CI. Tanzanians (OR: 3.2; 95% CI: 2.4 to 4.3; P < 0.001) and Kenyans (OR: 2.0; 95% CI: 1.6 to 2.6; P < 0.001) had higher risk of CI compared with Ugandans. Results were relatively unchanged in predictive models of NP-6, with the only difference being an additional significant effect of current CD4 cell count (coeff: 0.0; 95% CI: 0.0 to 0.0; P = 0.005).
CONCLUSIONS
Literacy, country, World Health Organization stage, and current CD4 cell count were associated with increased risk of cognitive dysfunction. Our findings help optimize care practices in Africa, illustrating the importance of strategies for early and effective viral-immunological control.
Identifiants
pubmed: 31904698
doi: 10.1097/QAI.0000000000002242
pmc: PMC7316185
mid: NIHMS1549540
pii: 00126334-202002010-00009
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
157-164Subventions
Organisme : NIMH NIH HHS
ID : K24 MH098759
Pays : United States
Organisme : NINDS NIH HHS
ID : UH3 NS105557
Pays : United States
Organisme : PEPFAR
Pays : United States
Références
Danforth K, Granich R, Wiedeman D, et al. Global mortality and morbidity of HIV/AIDS. In: Holmes KK, Bertozzi S, Bloom BR, et al, eds. Major Infectious Diseases. Washington, DC: World Health Organization; 2017.
INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281–290.
UNAIDS Joint United Nations Programme on HIV/AIDS. 90-90-90: ambitious treatment target to help end the AIDS epidemic. Available at: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf. Accessed February 25, 2019.
WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: What's New: November 2015. Geneva, Switzerland: World Health Organization; 2015.
UNAIDS Joint United Nations Programme on HIV/AIDS. Fast-track: ending the AIDS Epidemic by 2030. Available at: http://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf. Accessed February 25, 2019.
Levi J, Raymond A, Pozniak A, et al. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. BMJ Glob Heal. 2016;1:e000010.
Granich R, Gupta S, Hall I, et al. Status and methodology of publicly available national HIV care continua and 90-90-90 targets: a systematic review. PLoS Med. 2017;14:e1002253.
Cherutich P, Kim AA, Kellogg TA, et al. Detectable HIV viral load in Kenya: data from a population-based survey. PLoS One. 2016;11:e0154318.
Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59:1944–1950.
Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10:317–331.
Sacktor N. Changing clinical phenotypes of HIV-associated neurocognitive disorders. J Neurovirol. 2017;1:1–5.
Robertson R, Sacktor N, Valcour V, et al. Updated research nosology for HIV- associated neurocognitive disorders. Neurology. 2007;69:1789–1799.
Heaton RK, Franklin DR, Deutsch R, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis. 2015;60:473–480.
Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24:1243–1250.
Nightingale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13:1139–1151.
Joska JA, Westgarth-Taylor J, Myer L, et al. Characterization of HIV-Associated Neurocognitive Disorders among individuals starting antiretroviral therapy in South Africa. AIDS Behav. 2011;15:1197–1203.
Nakku J, Kinyanda E, Hoskins S. Prevalence and factors associated with probable HIV dementia in an African population: a cross-sectional study of an HIV/AIDS clinic population. BMC Psychiatry. 2013;13:126.
Tsegaw M, Andargie G, Alem G, et al. Screening HIV-associated neurocognitive disorders (HAND) among HIV positive patients attending antiretroviral therapy in South Wollo, Ethiopia. J Psychiatr Res. 2017;85:37–41.
Habib AG, Yakasai AM, Owolabi LF, et al. Neurocognitive impairment in HIV-1-infected adults in Sub-Saharan Africa: a systematic review and meta-analysis. Int J Infect Dis. 2013;17:e820–e831.
Kwasa J, Cettomai D, Lwanya E, et al. Lessons learned developing a diagnostic tool for HIV-associated dementia feasible to implement in resource-limited settings: pilot testing in Kenya. PLoS One. 2012;7:e32898.
Tozzi V, Balestra P, Galgani S, et al. Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retroviruses. 2003;19:643–652.
Gorman AA, Foley JM, Ettenhofer ML, et al. Functional consequences of HIV-associated neuropsychological impairment. Neuropsychol Rev. 2009;19:186–203.
Walker KA, Brown GG. HIV-associated executive dysfunction in the era of modern antiretroviral therapy: a systematic review and meta-analysis. J Clin Exp Neuropsychol. 2018;40:357–376.
Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorder—pathogenesis and prospects for treatment. Nat Rev Neurol. 2016;12:234–248.
Woods SP, Moore DJ, Weber E, et al. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev. 2009;19:152–168.
Heaton RK, Clifford DB, Franklin DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087–2096.
Ake JA, Polyak CS, Crowell TA, et al. Noninfectious comorbidity in the african cohort study (AFRICOS). Clin Infect Dis. 2018. 10.1093/cid/ciy981.
doi: 10.1093/cid/ciy981
Milanini B, Paul R, Bahemana E, et al. Limitations of the international HIV dementia scale in the current era. AIDS. 2018;32:2477–2483.
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.
Lewinsohn PM, Seeley JR, Roberts RE, et al. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging. 1997;12:277–287.
Bennett DA. How can I deal with missing data in my study? Aust N Z J Public Health. 2001;25:464–469.
Mukaka MM. Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24:69–71.
Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect Dis. 2013;13:976–986.
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382:1525–1533.
Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. Plos Med. 2013;10:e1001418.
Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis. 2013;26:17–25.
Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment. JAIDS J Acquir Immune Defic Syndr. 2007;45:174–182.
Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65–70.
Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol. 2011;11:148.
Ellis RJ, Letendre S, Vaida F, et al. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis. 2014;58:1015–1022.
Cross HM, Combrinck MI, Joska JA. HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes. S Afr Med J. 2013;103:758–762.
Eggers C, Arendt G, Hahn K, et al. HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol. 2017;264:1715–1727.
Foley JM, Ettenhofer ML, Kim MS, et al. Cognitive reserve as a protective factor in older HIV-positive patients at risk for cognitive decline. Appl Neuropsychol Adult. 2012;19:16–25.
Milanini B, Ciccarelli N, Fabbiani M, et al. Cognitive reserve and neuropsychological functioning in older HIV-infected people. J Neurovirol. 2016;22:575–583.
Morgan EE, Woods SP, Smith C, et al. Lower cognitive reserve among individuals with syndromic HIV-associated neurocognitive disorders (HAND). AIDS Behav. 2012;16:2279–2285.
Yakasai AM, Gudaji MI, Muhammad H, et al. Prevalence and correlates of HIV-associated neurocognitive disorders (HAND) in northwestern Nigeria. Neurol Res Int. 2015;2015:486960.
Lawler K, Jeremiah K, Mosepele M, et al. Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana. PLoS One. 2011;6:e17233.
Njamnshi AK, Bissek ACZK, Ongolo-Zogo P, et al. Risk factors for HIV-associated neurocognitive disorders (HAND) in sub-Saharan Africa: the case of Yaoundé-Cameroon. J Neurol Sci. 2009;285:149–153.
Dotson VM, Kitner-Triolo MH, Evans MK, et al. Effects of race and socioeconomic status on the relative influence of education and literacy on cognitive functioning. J Int Neuropsychol Soc. 2009;15:580.
Manly JJ, Touradji P, Tang MX, et al. Literacy and memory decline among ethnically diverse elders. J Clin Exp Neuropsychol. 2003;25:680–690.
Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012;11:1006–1012.
Dixon S, McDonald S, Roberts J. The impact of HIV and AIDS on Africa's economic development. BMJ. 2002;324:232–234.
Breuer E, Myer L, Struthers H, et al. HIV/AIDS and mental health research in sub-Saharan Africa: a systematic review. Afr J AIDS Res. 2011;10:101–122.
Chibanda D, Benjamin L, Weiss HA, et al. Mental, neurological, and substance use disorders in people living with HIV/AIDS in low- and middle-income countries. J Acquir Immune Defic Syndr. 2014;67(suppl 1):S54–S67.
Geldsetzer P, Ortblad K, Bärnighausen T. The efficiency of chronic disease care in sub-Saharan Africa. BMC Med. 2016;14:127.
Ingraham LJ, Aiken CB. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology. 1996;10:120–124.
Binder LM, Iverson GL, Brooks BL. To err is Human : “abnormal” neuropsychological scores and variability are common in healthy adults. Arch Clin Neuropsychol. 2009;24:31–46.